Naidu Kalaga Mahalakshmi, Srinivasarao Singireddi, Agnieszka Napiórkowska, Ewa Augustynowicz-Kopeć, Kumar Muthyala Murali Krishna, Chandra Sekhar Kondapalli Venkata Gowri
Department of Chemistry, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Shamirpet Mandal, Hyderabad 500 078, India.
Microbiology Department, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Bioorg Med Chem Lett. 2016 May 1;26(9):2245-50. doi: 10.1016/j.bmcl.2016.03.059. Epub 2016 Mar 15.
A series of thirty eight novel 3-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole and 1-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl/1,4-diazepan-1-yl)-2-(1H-indol-3-yl)substituted-1-one analogues were synthesised, characterised using various analytical techniques and evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain and two 'wild' strains Spec. 210 and Spec. 192. The titled compounds exhibited minimum inhibitory concentration (MIC) ranging from 6.16 to >200μM. Among the tested compounds, 7i, 7y and 7z exhibited moderate activity (MIC=24.03-29.19μM) and 7j exhibited very good anti-tubercular activity (MIC=6.16μM). Furthermore, 7i, 7j, 7y and 7z were found to be non-toxic against mouse macrophage cell lines when screened for toxicity. All the synthesised compounds were docked to pantothenate synthetase enzyme site to know deferent binding interactions with the receptor.
合成了一系列38种新型的3-(4-((取代-1H-1,2,3-三唑-4-基)甲基)哌嗪-1-基/1,4-二氮杂环庚烷-1-基)苯并[d]异恶唑和1-(4-(苯并[d]异恶唑-3-基)哌嗪-1-基/1,4-二氮杂环庚烷-1-基)-2-(1H-吲哚-3-基)取代-1-酮类似物,采用各种分析技术对其进行了表征,并评估了它们对结核分枝杆菌H37Rv菌株以及两种“野生”菌株Spec. 210和Spec. 192的体外抗结核活性。标题化合物的最低抑菌浓度(MIC)范围为6.16至>200μM。在测试的化合物中,7i、7y和7z表现出中等活性(MIC = 24.03 - 29.19μM),7j表现出非常好的抗结核活性(MIC = 6.16μM)。此外,在进行毒性筛选时,发现7i、7j、7y和7z对小鼠巨噬细胞系无毒。所有合成的化合物都与泛酸合成酶酶位点进行对接,以了解与受体的不同结合相互作用。